NLA101 in Adults Receiving High Dose Chemotherapy for AML

NCT03301597 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

146

Enrollment

INDUSTRY

Sponsor class

Stopped Development plan under review.

Conditions

Leukemia, Myeloid, Acute

Interventions

BIOLOGICAL: NLA101
DRUG: Standard of Care (SOC) chemotherapy

Sponsor

Nohla Therapeutics, Inc.